Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial.

Lorenzo Livi, Icro Meattini, Livia Marrazzo, Gabriele Simontacchi, Stefania Pallotta, Calogero Saieva, Fabiola Paiar, Vieri Scotti, Carla De Luca Cardillo, Paolo Bastiani, Lorenzo Orzalesi, Donato Casella, Luis Sanchez, Jacopo Nori, Massimiliano Fambrini, Simonetta Bianchi

Journal: European journal of cancer (Oxford, England : 1990) 2015;51(4):451-463

PMID: 25605582

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Accelerated partial breast irradiation (APBI) has been introduced as an alternative treatment method for selected patients with early stage breast cancer (BC). Intensity-modulated radiotherapy (IMRT) has the theoretical advantage of a further increase in dose conformity compared with three-dimensional techniques, with more normal tissue sparing. The aim of this randomised trial is to compare the local recurrence and survival of APBI using the IMRT technique after breast-conserving surgery to conventional whole-breast irradiation (WBI) in early stage BC.

METHODS

This study was performed at the University of Florence (Florence, Italy). Women aged more than 40years affected by early BC, with a maximum pathological tumour size of 25mm, were randomly assigned in a 1:1 ratio to receive either WBI or APBI using IMRT. Patients in the APBI arm received a total dose of 30 Gy to the tumour bed in five daily fractions. The WBI arm received 50Gy in 25 fractions, followed by a boost on the tumour bed of 10Gy in five fractions. The primary end-point was occurrence of ipsilateral breast tumour recurrences (IBTRs); the main analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT02104895.

FINDINGS

A total of 520 patients were randomised (260 to external WBI and 260 to APBI with IMRT) between March 2005 and June 2013. At a median follow-up of 5.0 years (Interquartile Range (IQR) 3.4-7.0), the IBTR rate was 1.5% (three cases) in the APBI group (95% confidence interval (CI) 0.1-3.0) and in the WBI group (three cases; 95% CI 0.0-2.8). No significant difference emerged between the two groups (log rank test p=0.86). We identified seven deaths in the WBI group and only one in the APBI group (p=0.057). The 5-year overall survival was 96.6% for the WBI group and 99.4% for the APBI group. The APBI group presented significantly better results considering acute (p=0.0001), late (p=0.004), and cosmetic outcome (p=0.045).

INTERPRETATION

To our knowledge, this is the first randomised study using the IMRT technique for APBI delivery. No significant difference in terms of IBTR and overall survival was observed between the two arms. APBI displayed a significantly better toxicity profile.

Address: Department of Radiation Oncology, University of Florence, Florence, Italy.; Department of Radiation Oncology, University of Florence, Florence, Italy. Electronic address: [email protected].; Medical Physics Unit, University of Florence, Florence, Italy.; Molecular and Nutritional Epidemiology Unit, ISPO (Cancer Research and Prevention Institute), University of Florence, Florence, Italy.; Radiotherapy Unit, Azienda Sanitaria 10, University of Florence, Florence, Italy.; Department of Surgery, University of Florence, Florence, Italy.; Diagnostic Senology Unit, University of Florence, Florence, Italy.; Gynecologic and Obstetrics Unit, University of Florence, Florence, Italy.; Division of Pathological Anatomy, Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy.

DOI: 10.1016/j.ejca.2014.12.013

Link outs

Free resources

Medical:

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Aged, Breast, Breast Neoplasms, Female, Humans, Middle Aged, Radiotherapy, Intensity-Modulated